Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis

Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis

Abstract Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute to hypoxemic respiratory failure, the most common cause of death, in patients with COVID‐19. Randomized controlled trials (RCTs) suggest differences in the effect of therapeutic heparin between moderat...

Full description

Bibliographic Details
Main Authors: Michelle Sholzberg, Bruno R. daCosta, Grace H. Tang, Hassan Rahhal, Musaad AlHamzah, Lisa Baumann Kreuziger, Fionnuala Ní Áinle, Mozah Obaid Almarshoodi, Paula D. James, David Lillicrap, Marc Carrier, Andrew Beckett, Michael Fralick, Saskia Middeldorp, Agnes Y. Y. Lee, Kevin E. Thorpe, Elnara Márcia Negri, Mary Cushman, Peter Jüni, the RAPID Trial Investigators
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anticoagulation
clinical trials
COVID‐19
heparin
meta‐analysis
Online Access:https://doi.org/10.1002/rth2.12638

Internet

https://doi.org/10.1002/rth2.12638

Similar Items